Kangstem Biotech Co. Ltd (217730) - Total Assets
Based on the latest financial reports, Kangstem Biotech Co. Ltd (217730) holds total assets worth ₩74.45 Billion KRW (≈ $50.45 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 217730 operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Kangstem Biotech Co. Ltd - Total Assets Trend (2015–2025)
This chart illustrates how Kangstem Biotech Co. Ltd's total assets have evolved over time, based on quarterly financial data. See Kangstem Biotech Co. Ltd book value and equity for net asset value and shareholders' equity analysis.
Kangstem Biotech Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Kangstem Biotech Co. Ltd's total assets of ₩74.45 Billion consist of 53.5% current assets and 46.5% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 2.4% |
| Accounts Receivable | ₩438.78 Million | 0.5% |
| Inventory | ₩814.51 Million | 1.0% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩9.21 Billion | 11.3% |
| Goodwill | ₩7.26 Billion | 8.9% |
Asset Composition Trend (2015–2025)
This chart illustrates how Kangstem Biotech Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Kangstem Biotech Co. Ltd market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kangstem Biotech Co. Ltd's current assets represent 53.5% of total assets in 2025, a decrease from 75.6% in 2015.
- Cash Position: Cash and equivalents constituted 2.4% of total assets in 2025, down from 20.0% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 19.0% of total assets, an increase from 3.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 11.3% of total assets.
Kangstem Biotech Co. Ltd Competitors by Total Assets
Key competitors of Kangstem Biotech Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
USA | $472.67 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $506.75 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
Kangstem Biotech Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.56 | 3.36 | 3.32 |
| Quick Ratio | 4.43 | 3.24 | 3.29 |
| Cash Ratio | 0.00 | 0.31 | 0.00 |
| Working Capital | ₩28.73 Billion | ₩16.56 Billion | ₩26.41 Billion |
Kangstem Biotech Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Kangstem Biotech Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.07 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 45.6% |
| Total Assets | ₩81.49 Billion |
| Market Capitalization | $134.49 Million USD |
Valuation Analysis
Below Book Valuation: The market values Kangstem Biotech Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Kangstem Biotech Co. Ltd's assets grew by 45.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Kangstem Biotech Co. Ltd (2015–2025)
The table below shows the annual total assets of Kangstem Biotech Co. Ltd from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩81.49 Billion ≈ $55.23 Million |
+45.56% |
| 2024-12-31 | ₩55.99 Billion ≈ $37.94 Million |
-31.10% |
| 2023-12-31 | ₩81.25 Billion ≈ $55.06 Million |
+0.82% |
| 2022-12-31 | ₩80.59 Billion ≈ $54.62 Million |
-21.87% |
| 2021-12-31 | ₩103.15 Billion ≈ $69.90 Million |
+25.02% |
| 2020-12-31 | ₩82.51 Billion ≈ $55.91 Million |
-27.40% |
| 2019-12-31 | ₩113.64 Billion ≈ $77.01 Million |
+55.26% |
| 2018-12-31 | ₩73.19 Billion ≈ $49.60 Million |
+59.42% |
| 2017-12-31 | ₩45.91 Billion ≈ $31.12 Million |
-3.22% |
| 2016-12-31 | ₩47.44 Billion ≈ $32.15 Million |
+89.90% |
| 2015-12-31 | ₩24.98 Billion ≈ $16.93 Million |
-- |
About Kangstem Biotech Co. Ltd
Kangstem Biotech Co., Ltd. a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases. The company's stem cell therapy products include Furestem-AD for treatment of subacute and chronic atopic dermatitis; Furestem-RA to treat rheumatoid arthritis; and Furestem-CD for treatment of active crohn's disease. It also provides stem cell conditioned media, such a… Read more